Genus Plc: URUS Group & Bovine Genetics Competition
Former URUS Group Executive
inpractise.com/articles/genus-plc-urus-group-and-bovine-genetics-competition
Former URUS Group Executive
Interview Transcript
This is a snippet of the transcript, sign up to read more.
I've been reading about these changes. What is the economic impact on genetics companies that don't own the sexing technology, like URUS Group or its subsidiaries, such as CRI? I presume they were using ST's technology for sex-sorted semen. Could you discuss the impact of sexing on the economics of genetics businesses?
It went from having no cost to becoming a major part of the expense line for companies like the URUS Group, Select Sires, and virtually all the different companies, including Genus. In the early phases, Genus worked with Sexing Technologies until they developed their own. This became a significant expense factor early on. Initially, there was a big price premium in the marketplace for that. Over time, the price has eroded somewhat, but the production efficiency of producing sexed semen has increased greatly. It's probably a trade-off between those two. Can I take a minute to talk about production efficiency? When you look at the economics of sexed semen, that's an important factor.
This is a snippet of the transcript, sign up to read more.
I've been reading about these changes. What is the economic impact on genetics companies that don't own the sexing technology, like URUS Group or its subsidiaries, such as CRI? I presume they were using ST's technology for sex-sorted semen. Could you discuss the impact of sexing on the economics of genetics businesses?
Early on, when producing sexed semen, if we were getting, say, five straws from a bull for conventional semen, we might only get one straw of sorted semen from the same amount of raw semen. It was a big sacrifice in terms of production. Efficiency has improved significantly now, and it depends on the bull, but it's much closer to one-to-one now than it has been. So, you aren't sacrificing any amount of doses, at least with the ST product that I'm familiar with.
This is a snippet of the transcript, sign up to read more.
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.